Details of the Drug Combinations

General Information of This Drug (ID: DM1IS6U)

Drug Name

Tenofovir DM1IS6U

Synonyms

Apropovir; PMPA; TFV; Tenefovir; GS 1275; GS 1278; GS1278; GNA & Tenofovir; HHA & Tenofovir; KS-5021; Viread (TN); Viread, Tenofovir; D,L-Tenofovir; PMPA-(R); Phosphonic acid, [[2-(6-amino-9H-purin-9; [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid; Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-(9CI); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Galanthus nivalis agglutinin (GNA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Hippeastrum hybrid agglutinin(HHA); (R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-(2-Phosphonylmethoxypropyl)adenine; (R)-PMPA

Indication

Disease Entry	ICD 11	Status	REF
Chronic hepatitis B virus infection	N.A.	Approved	[1]
Hepatitis B virus infection	1E51.0	Approved	[1]
Human immunodeficiency virus infection	1C62	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Anti-HIV Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

23 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Tenofovir + Simvastatin	DC6LVM9	Simvastatin	Hepatitis B	[3]
Tenofovir + Raltegravir	DC85GHN	Raltegravir	HIV Infections	[4]
Tenofovir + Raltegravir	DCEHPPH	Raltegravir	HIV	[5]
Tenofovir + Rilpivirine	DCOWAAF	Rilpivirine	AIDS	[6]
Tenofovir + Dolutegravir	DCVH2RE	Dolutegravir	AIDS	[6]
Tenofovir + Telbivudine	DCWX983	Telbivudine	Chronic Hepatitis B	[7]
Tenofovir + Entecavir	DCXIXJ5	Entecavir	Hepatitis B, Chronic	[8]
Tenofovir + Entecavir	DCYL3PT	Entecavir	Chronic Viral Hepatitis B Without Delta-agent	[9]
Tenofovir + Emtricitabine	DC4VA0W	Emtricitabine	Acute HIV Infection	[10]
Tenofovir + Emtricitabine	DC21DGG	Emtricitabine	HIV/AIDS	[11]
Tenofovir + Atazanavir	DC0AQOM	Atazanavir	Infection, Human Immunodeficiency Virus	[12]
Tenofovir + Emtricitabine	DC2KNZU	Emtricitabine	Infection, Human Immunodeficiency Virus	[13]
Tenofovir + Dolutegravir	DCTL991	Dolutegravir	HIV Infections	[14]
Tenofovir + Efavirenz	DC3BWC7	Efavirenz	HIV Infections	[15]
Tenofovir + Efavirenz	DCK1LPD	Efavirenz	HIV-1 Infection	[16]
Tenofovir + Efavirenz	DCLY8CK	Efavirenz	HIV Infections	[15]
Tenofovir + Lamivudine	DCMJWN4	Lamivudine	HIV Infections	[17]
Tenofovir + Lamivudine	DCBEIYG	Lamivudine	Human Immunodeficiency Virus	[18]
Tenofovir + Lamivudine	DCEBNVB	Lamivudine	HIV Infections	[19]
Tenofovir + Dolutegravir	DCFVOSL	Dolutegravir	Human Immunodeficiency Virus	[18]
Tenofovir + Emtricitabine	DC0E91Q	Emtricitabine	HIV-1-infection	[20]
Tenofovir + Efavirenz	DCC72B6	Efavirenz	HIV Infections	[21]
Tenofovir + Emtricitabine	DCSIUUP	Emtricitabine	HIV	[22]
------------------------------------------------------------------------------------


⏷ Show the Full List of 23 DrugCom(s)

References

1	Tenofovir FDA Label
2	Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother. 2009;19(4):165-76.
3	ClinicalTrials.gov (NCT00994773) Simvastatin for the Treatment of Chronic Hepatitis B
4	ClinicalTrials.gov (NCT00977756) IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
5	ClinicalTrials.gov (NCT01214759) Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
6	ClinicalTrials.gov (NCT03782142) Effect on HIV Medications on EPC Cells
7	ClinicalTrials.gov (NCT01588912) Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir
8	ClinicalTrials.gov (NCT00410202) Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
9	ClinicalTrials.gov (NCT01639066) Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B
10	ClinicalTrials.gov (NCT02475915) Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection
11	ClinicalTrials.gov (NCT03917420) Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract
12	ClinicalTrials.gov (NCT01384734) HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
13	ClinicalTrials.gov (NCT01803074) Study to Evaluate a HIV Drug for the Treatment of HIV Infection
14	ClinicalTrials.gov (NCT02386098) Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults
15	ClinicalTrials.gov (NCT00350272) Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
16	ClinicalTrials.gov (NCT01489046) Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
17	ClinicalTrials.gov (NCT00100048) A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
18	ClinicalTrials.gov (NCT03988452) Nucleosides And Darunavir/Dolutegravir In Africa
19	ClinicalTrials.gov (NCT02369965) Test Albuvirtide in Experienced Patients. U.S. National Institutes of Health.
20	ClinicalTrials.gov (NCT03360682) Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients
21	ClinicalTrials.gov (NCT02945163) Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy
22	ClinicalTrials.gov (NCT01335620) The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age